Reversibility of acute demyelinating lesions in relapsing-remitting multiple sclerosis.
1
Citation
10
Reference
10
Related Paper
Abstract:
Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) of presumed autoimmune etiology and characterized by a relapsing-remitting course. Brain magnetic resonance imaging (MRI) has emerged as the most sensitive investigation to detect demvelitiation in MS. Furthermore, acute relapses of MS have been associated with breakdown of the blood-brain barrier (BBB) seen as contrast enhancement on brain MR( TI-weighted images. Recently, we encountered a case of an acute relapse in a patient with known MS. ireatment with h igh-dose intravenous methylprednisolone (IVMP) resulted in clinical recovery as well as resolution of brain MRI abnormalities. This patient represents a striking case of complete reversibility of acute demyelinating lesions seen on brain MRI scans.Keywords:
Demyelinating disease
Etiology
Relapsing remitting
Demyelinating Disorder
Cite
Relapsing remitting
Cite
Citations (12)
Availability of oral disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) may affect injectable DMT (iDMT) treatment patterns.The objective of this paper is to evaluate iDMT persistency, reasons for persistency lapses, and outcomes among newly diagnosed RRMS patients.Medical records of 300 RRMS patients initiated on iDMT between 2008 and 2013 were abstracted from 18 US-based neurology clinics. Eligible patients had ≥3 visits: pre-iDMT initiation, iDMT initiation (index), and ≥1 visit within 24 months post-index. MS-related symptoms, relapses, iDMT treatment patterns (i.e. persistency, discontinuation, switching, and restart), and reasons for non-persistency were tracked for 24 months.At 24 months, iDMT persistency was 61.0%; 28.0% of patients switched to another DMT, 8.0% discontinued, and 3.0% stopped and restarted the same iDMT. The most commonly identified reasons for non-persistency were perceived lack of efficacy (22.2%), adverse events (18.8%), and fear of needles/self-injecting (9.4%). At 24 months, 38.0% of patients had experienced a relapse and 11.0% had changes in MRI lesion counts. Patients without MS-related symptoms at index reported increases in the incidence of these symptoms at 24 months.Non-persistency with iDMT remains an issue in the oral DMT age. Many patients still experienced relapses and disease progression, and should consider switching to more effective therapies.
Relapsing remitting
Cite
Citations (9)
Relapsing remitting
Intrathecal
Cite
Citations (0)
Relapsing remitting is the most common type of multiple sclerosis, affecting approximately 85% of all patients. Previous evidence has suggested that the risk factors for developing relapsing remitting multiple sclerosis is multifactorial. Similarly, it has been suggested that these factors also influence the risk of relapse. This article critically appraises and evaluates a systematic review that examined multiple factors associated with the risk of relapse for relapsing remitting multiple sclerosis.
Relapsing remitting
Cite
Citations (0)
Relapsing remitting
Dimethyl fumarate
Cite
Citations (2)
Relapsing remitting
Discontinuation
Natalizumab
Cite
Citations (15)
CCL5
Cite
Citations (11)
Relapsing remitting
Medical record
McDonald criteria
Cite
Citations (0)
Cladribine
Natalizumab
Dimethyl fumarate
Teriflunomide
Relapsing remitting
Cite
Citations (2)
Relapsing remitting
Diagnosis code
Cite
Citations (1)